Tenderwize
Retour à la recherche

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2028 · 643 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Conclusion of discount contracts for Infliximab (subcutaneous injection) with multiple pharmaceutical entrepreneurs.
  • Uniform contract terms; no individual negotiations.
Afficher le résumé complet

Open-House procedure for discount contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Infliximab (subcutaneous injection). No competitive selection; any qualified pharmaceutical entrepreneur can join. No estimated value provided. The lead buyer is Techniker Krankenkasse, with several other German statutory health insurance funds. The contract term is up to 24 months starting June 1, 2026, ending May 31, 2028. Participation is open throughout the contract term. No procurement documents were analyzed.

Risques

No estimated contract value, framework maximum value, or budget provided. Revenue potential is unknown.

Contract ends automatically upon patent expiry or loss of market exclusivity. Could be terminated earlier than the max...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG.
  • Must hold a valid marketing authorization for the product or be entitled to place the product on the market.

Administrative

  • Must provide a self-declaration on authorization and company (Anlage 4).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Discount Contracts for Infliximab (Subcutaneous Injection)

Conclusion of discount contracts for the active substance Infliximab (subcutaneous injection) with any eligible pharmaceutical entrepreneur under an open-house model. No exclusivity; uniform conditions apply.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Date limite

Deadline May 30, 2028

Détails de la procédure

Date de publication
19 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
266368-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3